Essential Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Essential Partners’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-339	Closed	-$308	–	2737
2025 Q2	$308	Buy	+339	New	+$201	﹤0.01%	1838

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's LCTX Position: Q3 2025 in Review

Essential Partners sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 339 shares — an estimated $308 sold.

Essential Partners first reported a position in LCTX in Q2 2025 and held it in 1 quarter. The position peaked at $308 in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

Essential Partners reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 339 Lineage Cell Therapeutics shares in Q3 2025, an estimated $308.
Essential Partners first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 1 quarter.
Essential Partners's Lineage Cell Therapeutics position peaked at $308 in Q2 2025.
112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.